La cadena de opciones muestra datos clave de las opciones de acciones de Psyence Biomedical a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Psyence Biomedical..

Psyence Biomedical (NASDAQ:PBM) Bolsa, Cadena de Opciones

Psyence Biomedical

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

Earnings

Equities

News

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

Los futuros caen ante la &#34;Triple Brujería&#34; y nuevos datos de inflación. ¿Qué dicen los analistas sobre el mercado?

Futuros de EE.UU. caen antes de datos clave de inflación y Triple Brujería

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical Ltd

PACIFIC BAY MINERALS LTD by Pacific Bay Minerals Ltd.

Pacific Bay Minerals Ltd

PACIFIC BOOKER MINERALS by Pacific Booker Minerals Inc.

Pacific Booker Minerals Inc

PGIM S&P 500 Buffer 20 ETF - March

PT BUMI RESOURCES TBK by PT Bumi Resources TBK

PT Bumi Resources Tbk

PT BUMI RESTBK UNSP/ADR by PT Bumi Resources TBK

PGIM S&P 500 Buffer 20 ETF - May

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares increased by 8.8% to $0.3 during Tuesday's after-market session. The market value of their outstanding shares is at $18.8 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock rose 8.14% to $0.69. The market value of their outstanding shares is at $111.0 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 8.0% to $0.88. The company's market cap stands at $14.5 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock moved upwards by 7.77% to $0.97. The company's market cap stands at $14.7 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 6.66% to $1.12. The market value of their outstanding shares is at $2.3 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 6.36% to $0.33. The market value of their outstanding shares is at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares decreased by 26.2% to $2.14 during Tuesday's after-market session. The market value of their outstanding shares is at $77.5 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) stock decreased by 16.76% to $3.08. The company's market cap stands at $204.8 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock decreased by 16.26% to $0.24. The company's market cap stands at $20.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 14.35% to $5.97. The market value of their outstanding shares is at $17.2 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares declined by 8.28% to $0.75. The market value of their outstanding shares is at $17.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 6.89% to $4.8. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

BMEA

CGTX

CRDF

EYEN

GOVX

HSDT

IBIO

IRWD

SLRX

XAIR

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock increased by 67.5% to $6.35 during Friday's pre-market session. The market value of their outstanding shares is at $23.6 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock rose 20.19% to $1.25. The market value of their outstanding shares is at $23.4 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock increased by 10.92% to $5.79. The market value of their outstanding shares is at $3.3 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock increased by 10.28% to $1.3. The market value of their outstanding shares is at $20.4 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) stock moved upwards by 9.98% to $0.98. The market value of their outstanding shares is at $45.8 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock moved upwards by 9.52% to $1.38. The company's market cap stands at $111.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) stock declined by 23.0% to $3.5 during Friday's pre-market session. The market value of their outstanding shares is at $40.0 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares fell 20.28% to $0.41. The market value of their outstanding shares is at $3.1 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares fell 15.95% to $0.28. The market value of their outstanding shares is at $7.7 million. </li>
<li>NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares fell 14.8% to $11.17. The company's market cap stands at $366.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares declined by 13.23% to $0.36. The company's market cap stands at $1.7 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares decreased by 13.0% to $0.58. The company's market cap stands at $25.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLRX

BMGL

CERO

CLGN

ENTO

GNPX

HBIO

IMAB

NPCE

RVPH

VSEE

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) stock moved upwards by 178.2% to $3.95 during Friday's regular session. The company's market cap stands at $253.7 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock increased by 26.52% to $0.72. The company's market cap stands at $24.2 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) shares increased by 25.62% to $22.11. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 25.47% to $0.28. The company's market cap stands at $40.0 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock moved upwards by 25.33% to $1.88. The company's market cap stands at $94.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 22.8% to $5.43. The market value of their outstanding shares is at $3.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 67.3% to $0.01 during Friday's regular session. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 22.48% to $0.01. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 19.63% to $0.65. The company's, Q2 earnings came out yesterday. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 18.92% to $0.04. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock declined by 18.44% to $3.15. The company's market cap stands at $33.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock declined by 18.15% to $2.12. The company's market cap stands at $13.0 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

APDN

ATPC

AYTU

BDSX

HCTI

INZY

LTRN

NCNA

PLRZ

RANI

12 Health Care Stocks Moving In Friday's Intraday Session

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares rose 68.2% to $4.81 during Thursday's pre-market session. The market value of their outstanding shares is at $3.9 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock moved upwards by 36.2% to $0.02. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock rose 28.98% to $0.89. The market value of their outstanding shares is at $5.8 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock moved upwards by 11.56% to $3.28. The market value of their outstanding shares is at $123.5 million. </li>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) shares moved upwards by 10.63% to $1.55. The company's market cap stands at $48.5 million. </li>
<li>Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) stock increased by 10.42% to $54.23. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) stock fell 31.3% to $6.61 during Thursday's pre-market session. The market value of their outstanding shares is at $454.5 million. As per the press release, Q1 earnings came out today. </li>
<li>Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) stock decreased by 16.71% to $10.77. The market value of their outstanding shares is at $2.7 billion. As per the news, the Q1 earnings report came out today. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock decreased by 14.65% to $2.68. The market value of their outstanding shares is at $12.2 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 12.08% to $0.4. The market value of their outstanding shares is at $1.8 million. </li>
<li>Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) stock decreased by 11.72% to $6.78. The market value of their outstanding shares is at $2.0 billion. The company's, Q1 earnings came out today. </li>
<li>Greenwich LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLSI#NASDAQ">GLSI</a>) stock fell 10.9% to $9.0. The company's market cap stands at $119.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRV

ADIL

ARVN

BCDA

CNMD

FOLD

GLSI

LGMK

NAOV

SERA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock increased by 61.0% to $12.98 during Friday's regular session. The company's market cap stands at $8.7 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 42.96% to $2.26. The company's market cap stands at $31.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares rose 23.66% to $0.28. The market value of their outstanding shares is at $3.9 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) stock rose 15.48% to $7.68. The market value of their outstanding shares is at $45.5 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 15.06% to $3.97. The company's market cap stands at $2.1 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 14.45% to $0.53. The market value of their outstanding shares is at $2.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares declined by 36.9% to $7.86 during Friday's regular session. The company's market cap stands at $25.4 million. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock fell 36.76% to $23.21. The company's market cap stands at $17.1 billion. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares fell 33.66% to $0.6. The company's market cap stands at $9.0 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock declined by 23.75% to $1.43. The company's market cap stands at $21.1 million. </li>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock decreased by 21.4% to $1.02. The company's market cap stands at $85.6 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) stock declined by 21.1% to $15.47. The market value of their outstanding shares is at $101.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COEP

CYCC

INTS

JAGX

NDRA

RBOT

SMMT

STRO

SXTC

VYNE

<a href="https://www.biospace.com/press-releases/psyence-biomed-announces-usd-500-000-follow-on-investment-in-psylabs-and-global-ibogaine-supply-agreement">https://www.biospace.com/press-releases/psyence-biomed-announces-usd-500-000-follow-on-investment-in-psylabs-and-global-ibogaine-supply-agreement</a>
New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development. This follow-on investment underscores Psyence BioMed's commitment to building a vertically integrated, multi-asset psychedelics biotech platform with robust supply chain security and clinical development capabilities.
This new capital investment builds on the exclusive, royalty-bearing IP licensing agreement formalized between the two companies in September 2024, following an initial investment where Psyence BioMed acquired an 11.13% equity stake in PsyLabs. Under the terms of that agreement, PsyLabs supplies Psyence BioMed with pharmaceutical-grade, EU-GMP, nature-derived (non-synthetic) psilocybin for use in future clinical trials and eventual commercialization in substance use disorders (SUD).
In parallel with this financial commitment, Psyence BioMed has secured an exclusive right of first refusal in respect of the worldwide supply of pharmaceutical-grade, nature-derived Ibogaine. Under this agreement, PsyLabs will grant Psyence BioMed a right of first refusal to acquire the exclusive rights to a dedicated supply of Ibogaine for evaluation in the treatment of SUD, including Alcohol Use Disorder (AUD). This exclusive partnership further strengthens Psyence BioMed's integrated development strategy, ensuring access to high-quality psychedelic compounds to support its growing clinical pipeline and diversification into multiple therapeutic areas.
Ibogaine, a naturally occurring psychoactive substance derived from the Tabernanthe iboga plant, has shown promise in early-stage research for its unique ability to interrupt SUDs, offering a novel approach to addiction treatment. Existing treatment options for SUDs and AUD remain limited in effectiveness, highlighting the urgent need for new solutions.

Contracts

'Psyence BioMed Announces $500,000 Follow-On Investment In PsyLabs And Global Ibogaine Supply Agreement' - BioSpace

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 190.8% to $8.55 during Tuesday's pre-market session. The company's market cap stands at $6.4 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 32.42% to $0.58. The market value of their outstanding shares is at $2.6 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock rose 32.33% to $2.38. The company's market cap stands at $3.5 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares moved upwards by 27.36% to $2.67. The company's market cap stands at $13.1 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock increased by 22.32% to $3.89. The company's market cap stands at $8.6 million. </li>
<li>Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) shares increased by 20.07% to $27.51. The market value of their outstanding shares is at $1.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock decreased by 51.2% to $3.66 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) stock decreased by 46.37% to $1.4. The market value of their outstanding shares is at $109.6 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock declined by 30.25% to $8.05. The company's market cap stands at $209.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 19.02% to $0.7. The company's market cap stands at $8.0 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 16.44% to $0.27. The company's market cap stands at $2.0 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock decreased by 16.17% to $1.09. The market value of their outstanding shares is at $52.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

CVRX

MYNZ

NAYA

PCRX

PHLT

PTIX

STTK

SXTP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock moved upwards by 17.7% to $1.13. The market value of their outstanding shares is at $6.6 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 16.29% to $3.24. The market value of their outstanding shares is at $8.8 million. As per the press release, Q4 earnings came out today. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares moved upwards by 10.48% to $0.55. The market value of their outstanding shares is at $9.3 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock fell 11.2% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares declined by 8.9% to $2.51. The company's market cap stands at $3.7 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 8.61% to $0.85. The market value of their outstanding shares is at $60.8 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock declined by 7.83% to $0.34. The market value of their outstanding shares is at $17.8 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares decreased by 6.67% to $0.56. The market value of their outstanding shares is at $2.5 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock declined by 6.64% to $4.08. The market value of their outstanding shares is at $84.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVM

BIAF

BNGO

CMPX

CTOR

EVOK

NUTX

PSTV

TLPH

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares rose 76.9% to $0.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $20.3 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock rose 57.77% to $2.13. The market value of their outstanding shares is at $8.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock moved upwards by 28.32% to $0.99. The market value of their outstanding shares is at $2.2 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock increased by 16.41% to $1.56. The company's market cap stands at $6.0 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) shares increased by 13.89% to $1.18. The market value of their outstanding shares is at $39.9 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock moved upwards by 11.95% to $0.52. The company's market cap stands at $96.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares decreased by 26.2% to $0.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares decreased by 24.59% to $1.81. The company's market cap stands at $128.9 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock fell 19.3% to $0.05. The market value of their outstanding shares is at $5.1 million. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares declined by 15.71% to $5.1. The company's market cap stands at $201.3 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 15.45% to $1.15. The market value of their outstanding shares is at $31.6 million. </li>
<li>Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares fell 10.55% to $19.26. The company's market cap stands at $21.8 billion. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BACK

LUNG

OKYO

SLXN

TEVA

TNXP

TRIB

ZNTL

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock moved upwards by 139.4% to $12.02 during Monday's pre-market session. The market value of their outstanding shares is at $36.3 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock increased by 86.24% to $3.25. The company's market cap stands at $7.2 million. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 85.3% to $1.53. The company's market cap stands at $53.4 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock increased by 51.7% to $2.67. The market value of their outstanding shares is at $2.8 million. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) stock rose 23.22% to $1.91. The market value of their outstanding shares is at $92.1 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock moved upwards by 16.63% to $0.7. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares declined by 25.6% to $0.06 during Monday's pre-market session. The company's market cap stands at $6.6 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock declined by 23.08% to $0.7. The market value of their outstanding shares is at $2.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 18.87% to $2.58. The company's market cap stands at $2.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 15.8% to $0.52. The company's market cap stands at $96.2 million. </li>
<li>Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) shares fell 13.42% to $24.01. The market value of their outstanding shares is at $203.0 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares declined by 13.15% to $0.39. The company's market cap stands at $17.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ELMD

GTBP

HCWB

IKNA

PHIO

RAPT

TRAW

12 Health Care Stocks Moving In Monday's Pre-Market Session

WIIM

Psyence Biomedical shares are trading lower after the company announced a $2M private placement.

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence Biomed" or the "Company") today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant in a private placement. The series A common warrants and short-term series B common warrants will have an exercise price of $2.00 per share and will be exercisable immediately upon issuance. The series A common warrants will expire five years from the date of issuance and the short-term series B common warrants will expire two years from the date of issuance. The private placement is expected to close on or about December 24, 2024, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The gross proceeds from the offering are expected to be approximately $2.0 million, prior to deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Offerings

Psyence Biomed Announces $2M Private Placement

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing requirements.
As previously announced, Psyence Biomed requested to be transferred from The Nasdaq Global Market to The Nasdaq Capital Market, effective November 15, 2024. As a result of this transfer, the Company regained compliance with listing rules 5550(a)(5), the $1.0 million minimum market value of publicly held shares requirement, and 5550(b)(1), the $2.5 million minimum stockholders' equity requirement.
Additionally, the Company obtained shareholder approval during its Annual General Meeting on November 12, 2024 to effect a 75-for-1 share consolidation. This share consolidation, which went into effect on November 26, 2024, was intended to address Nasdaq's listing rule 5550(a)(2), the $1 minimum bid price requirement. As the Company's shares have traded above $1 for the subsequent 18 trading days following the share consolidation, the minimum bid price requirement has been formally satisfied.

Government

Regulations

Psyence Biomed Regains Nasdaq Compliance After Share Consolidation

Psyence Biomedical Files Prospectus Relates To Potential Offer, Sale, From Time To Time 10.9M Common Shares By Selling Securityholders

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares rose 114.6% to $1.03 during Friday's pre-market session. The company's market cap stands at $3.8 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares increased by 67.34% to $5.79. The market value of their outstanding shares is at $744.9 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares moved upwards by 62.19% to $3.99. The company's market cap stands at $3.3 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares increased by 37.77% to $0.6. The company's market cap stands at $8.3 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares rose 29.25% to $30.75. The market value of their outstanding shares is at $162.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 16.55% to $3.45. The market value of their outstanding shares is at $3.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock declined by 53.1% to $0.16 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) stock decreased by 38.5% to $1.23. The market value of their outstanding shares is at $77.1 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares declined by 32.43% to $0.44. The market value of their outstanding shares is at $2.2 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock decreased by 21.86% to $0.93. The company's market cap stands at $44.9 million. </li>
<li>Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares declined by 20.14% to $82.61. The company's market cap stands at $366.9 billion. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) shares decreased by 17.71% to $2.51. The company's market cap stands at $10.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

BCAB

GALT

ISPC

MNPR

QNRX

SSKN

Shares of FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) rose sharply in today's pre-market trading as the company posted stronger-than-expected <a href="https://www.benzinga.com/news/earnings/24/12/42605034/fedex-stock-rallies-on-better-than-expected-q2-eps-freight-spin-off-announcement">results for its second quarter</a>.
The company also announced that it has decided to pursue a full separation of FedEx Freight through the capital markets, creating a new publicly traded company.
FedEx shares jumped 8.7% to $299.80 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) gained 80.5% to $0.3070 in pre-market trading after the company announced it was granted an extension to provide compliance evidence for a continued Nasdaq listing.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) gained 67.4% to $4.12 in pre-market trading fater jumping more than 60% on Thursday. The company announced it has entered into an IP licensing and mutual exclusivity agreement with Optimi Health Corp.</li>
<li>Ocean Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) climbed 62.5% to $0.9576 in pre-market trading.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) gained 52.8% to $4.08 in pre-market trading after jumping 317% on Thursday.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) rose 44.5% to $5.00 in pre-market trading as the company announced the FDA approval of SYMVESS&#x2122; (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma.</li>
<li>Aadi Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AADI#NASDAQ">AADI</a>) gained 35.3% to $3.14 in pre-market trading after the company secured $100 million PIPE financing and announced the sale of FYARRO for $100 million.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) gained 26.9% to $1.19 in pre-market trading after the company announced 7.85 million of its shares was acquired by Gilead Sciences.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) rose 17.4% to $8.78 in pre-market trading after dipping over 12% on Thursday.</li>
<li>Clearwater Paper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) gained 11.8% to $27.62 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares tumbled 49.5% to $0.1785 in pre-market trading after the company announced notice of delisting and failure to satisfy continued listing rules.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) declined 36.4% to $7.10 in pre-market trading after jumping around 410% on Thursday.</li>
<li>Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares fell 26.7% to $0.2998 in pre-market trading after jumping 56% on Thursday. Cara Therapeutics recently announced it entered into an all-stock merger with Tvardi Therapeutics.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) fell 25.8% to $76.80 in pre-market trading. Novo Nordisk said CagriSema demonstrated weight loss in adults with obesity or overweight in the REDEFINE 1 trial.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) shares dipped 25.2% to $0.9730 in pre-market trading after climbing 65% on Thursday.</li>
<li>Mobix Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) fell 24.5% to $1.57 in today's pre-market trading after reporting third-quarter results.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) dipped 23.6% to $1.94 in pre-market trading. Zoomcar said it launched Zoomcar Cabs, which are affordable car rentals with drivers as a new offering.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares fell 18.1% to $13.72 in pre-market trading. Mesoblast shares jumped over 36% on Thursday after the company announced the FDA approved Ryoncilas the first mesenchymal stromal cell therapy in the United States.</li>
<li>Candel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) fell 13.1% to $8.66 in pre-market trading after jumping over 52% on Thursday.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) fell 11.1% to $13.46 in pre-market trading after declining 41% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42609619/sp-500-nasdaq-end-in-red-as-investor-sentiment-declines-micron-tumbles-after-sales-miss-greed-index-in-extreme-fear-zone">S&amp;P 500, Nasdaq End In Red As Investor Sentiment Declines, Micron Tumbles After Sales Miss: Greed Index In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

U.S. stock futures declined on Friday, ahead of the &#8220;Triple Witching&#8221; hour, which is expected to see the expiry of about $6.6 trillion options, for the quarter.
This comes after the market fell on Wednesday after the Federal Reserve&#8217;s hawkish cut and ended mixed on Thursday. In Friday&#8217;s premarket, all four major indices were trading lower.
The 10-year and two-year Treasury notes yielded 4.55% and 4.28%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025 decision was at 89.3%, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
Investors will receive another critical economic data point on Friday with the release of the November personal consumption expenditures (PCE) inflation index. This release follows other inflation indicators that suggest price increases accelerated in November.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.12%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.78%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.57%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.13%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 1.16% to $579.30&nbsp;and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 1.23% to $507.83, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The S&amp;P 500 ended the day essentially unchanged after giving up earlier gains. The Nasdaq 100 fell 0.5%, fluctuating between small gains and losses throughout the session.
However, Dow Jones ended marginally higher, breaking its 10-day losing streak.
Most sectors on the S&amp;P 500 closed on a negative note, with materials, real estate, and energy stocks recording the biggest losses on Thursday. However, utilities and financials stocks bucked the overall market trend, closing the session higher.
Thursday&#8217;s economic data showed a revision upward in one of the Fed&#8217;s preferred inflation measures to 2.2%.
As Fed Chair Jerome Powell has indicated that further easing would require additional progress on inflation, market participants will now focus on the final significant economic data point of the year: November&#8217;s personal consumption expenditures, due out on Friday.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.10%</td>
<td>19,372.77</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.087%</td>
<td>5,867.08</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.036%</td>
<td>42,342.24</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.45%</td>
<td>2,221.50</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
The &#8220;Triple Witching&#8221; hour is a quarterly event that occurs during the final hour of trade on the third Friday of March, June, September, and December. During this period, contracts for stock index futures, stock index options, and stock options all expire at the same time.
According to the Chairman and Founder of Navellier &amp; Associates, Louis Navellier, &#8220;The timing of buying the dip is complicated by options expiration tomorrow and Christmas next week, but a recovery by the end of the year would not surprise anyone.&#8221;
He also said, &#8220;In my opinion, the stock and bond market reactions to the FOMC Statement, dot plot, and Fed Chairman Powell's press conference were grossly overdone and eviscerated all the stock market gains since the Presidential election.&#8221;
According to him, both France and Germany are in the midst of a political crisis and are "headless" until new leadership emerges. &#8220;As a result, I am expecting up to four Fed rate cuts in 2025 as collapsing interest rates in the eurozone also cause U.S. Treasury yields to decline,&#8221; he said.
However, Tom Lee, managing partner and head of research at Fundstrat Global Advisors, thinks <a href="https://www.benzinga.com/markets/equities/24/12/42608297/tom-lee-explains-why-fewer-cuts-in-2025-could-boost-the-market-urges-investors-to-buy-the-dip-amid-recent-volatility#:~:text=What%20Happened%3A%20%E2%80%9CThe%20fewer%20cuts,on%20Thursday%2C%20according%20to%20Fundstrat.&amp;text=%2C%20suffering%20its%20steepest%20one%2Dday%20decline%20since%20September%202022">fewer cuts are better for the economy</a>.
"The fewer cuts [the Fed does] in 2025, it actually is better for this bull market because it provides a lot of future ammunition to protect the economy," he said.
"I know yesterday's (Wednesday&#8217;s) pullback was really painful, but to us, the fundamentals supporting stocks are intact.&#8221;
Carson Research&#8217;s vice president and global macro strategist, Sonu Varghese called 2024 a &#8220;strong&#8221; year for U.S. stocks, even with the recent pullback.
&#8220;The fallout from the Fed meeting wiped out post-election gains across large swaths of the market, including value stocks and mid-cap and small-cap stocks, though looking back over the entire year, almost every major category is up double-digits so far, across style (value – core – growth) and capitalization (large – mid &#8211; small). For comparison the MSCI All-Cap World ex US Net Index is up just 7.2% year to date. That should tell you how strong of a year 2024 has been for US stocks, even with the recent pullback,&#8221; Varghese said in a note.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Important data is slated to be released on Friday that will help investors to determine the future course of action.
<ul>
<li>On Friday, personal income and spending data along with core and headline PCE index data for November will be released at 8:30 a.m., ET.</li>
<li>Consumer sentiment data for December will be released at 10:00 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) was up 105% in premarket after it inked an IP licensing and mutual exclusivity agreement with Optimi Health Corp., a Canadian psychedelics pharmaceutical manufacturer.</li>
<li>Humacyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) was up 52.31% in premarket after it received FDA approval for SYMVESS, a bioengineered human tissue designed as a universally implantable vascular conduit for arterial injury treatment.</li>
<li>Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) was down 3.37% after issuing <a href="https://www.benzinga.com/24/12/42610441/nikes-new-ceo-says-we-lost-our-obsession-with-sport-as-he-rebukes-old-strategies-on-performance-marketing-isolation-of-wholesalers-aims-to-create-demand">lower revenue guidance</a> and additional gross margin pressure given the higher demand creation expenses.</li>
<li>FedEx Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) was 7.33% higher after it posted stronger-than-expected results for its second quarter. The company also announced that it has decided to pursue a full separation of FedEx Freight through the capital markets, creating a new publicly traded company.</li>
<li>BlackBerry Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) was down 5.03% as it expects fourth-quarter revenue in the range of $126 million to $135 million versus the estimates of $161.49 million.</li>
<li>Winnebago Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) was up 2.04% as analysts expect it to post quarterly earnings at 20 cents per share on revenue of $672.23 million before the opening bell.</li>
<li>Carnival Corporation. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) fell 1.11% as it is expected to report quarterly earnings at 8 cents per share on revenue of $5.93 billion before the opening bell.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were lower in the early New York session by 2.75% to hover around $68.66 per barrel.
The gold spot index was up by 0.42% to $2,619.24 per ounce. The Dollar Index was down 0.16% to 108.239 level.
Asian markets declined on Friday, as Hong Kong&#8217;s Hang Seng, South Korea&#8217;s Kospi, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, China&#8217;s CSI 300 and Australia&#8217;s ASX 200 index fell. Most European markets were also in the red in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42610958/expecting-up-to-four-fed-rate-cuts-in-2025-says-this-analyst-despite-hawkish-powell-saying-it-was-close-on-the-decision-to-cut-or-not-heres-why">Hawkish Powell Aside, This Analyst Expects 4 Fed Rate Cuts In 2025: Here&#8217;s Why</a></li>
</ul>
Photo courtesy: Wikimedia

US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares moved upwards by 376.8% to $3.19 during Thursday's pre-market session. The market value of their outstanding shares is at $13.7 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock rose 50.2% to $18.4. The company's market cap stands at $2.0 billion. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 38.56% to $2.12. The market value of their outstanding shares is at $1.7 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock moved upwards by 35.45% to $1.49. The market value of their outstanding shares is at $76.7 million. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock rose 33.78% to $9.98. The company's market cap stands at $578.3 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock rose 26.21% to $4.77. The market value of their outstanding shares is at $10.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 35.1% to $0.43 during Thursday's pre-market session. The market value of their outstanding shares is at $5.9 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 26.75% to $2.41. The market value of their outstanding shares is at $10.1 million. </li>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock fell 20.01% to $11.2. The company's market cap stands at $681.5 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) stock decreased by 17.87% to $3.31. The market value of their outstanding shares is at $29.5 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares fell 13.93% to $3.4. The market value of their outstanding shares is at $3.2 million. </li>
<li>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) stock fell 12.85% to $390.0. The market value of their outstanding shares is at $100.4 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTH

MRKR

OMER

PLRX

VRTX

Press Releases

"Power Nickel (TSX.V: PNPN) (OTCQB: PNPNF) Announces Dividend – MIGI, PRFX, PBM, CSDX Stocks Trending Now!"

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Financing

Psyence Biomed Announces $2.0 Million Private Placement

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Health Care

Management

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Comments

Psyence Biomedical

Psyence Biomedical (PBM) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL